Torii Pharmaceutical Co Ltd 2018 AR2
The report details Torii Pharmaceutical Co., Ltd.'s business and CSR activities for the fiscal year ended December 31, 2018. During the year, the company formulated its 'Medium-Term Management Plan 2021' to address a challenging business environment, including the termination of exclusive marketing rights for six anti-HIV drugs. In its environmental initiatives, Torii achieved its company-wide greenhouse gas emissions target, reducing total CO2 emissions to 6,326 t-CO2. The company also reported that women represented 7.1% of board members and 6.4% of management positions, while continuing to promote compliance and social contribution activities.
Company: Torii Pharmaceutical Co Ltd
Sector: Health Care
Country: Japan
Year: 2018
Type: AR2
Pages: 52
Torii Pharmaceutical Co Ltd
Annual Report
The report details Torii Pharmaceutical Co., Ltd.'s business and CSR activities for the fiscal year ended December 31, 2018. During the year, the company formulated its 'Medium-Term Management Plan 2021' to address a challenging business environment, including the termination of exclusive marketing rights for six anti-HIV drugs. In its environmental initiatives, Torii achieved its company-wide greenhouse gas emissions target, reducing total CO2 emissions to 6,326 t-CO2. The company also reported that women represented 7.1% of board members and 6.4% of management positions, while continuing to promote compliance and social contribution activities.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2018
Reporting Period
Jan 1, 2018 - Dec 31, 2018
Fiscal Year
2018
Published
Jun 15, 2019
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Women on Board
Women in Management
Employees